Skip to main content
SpringerLink
Log in

Selecting Neuromuscular-Blocking Drugs for Elderly Patients

  • Therapy In Practice
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

The physiological changes that occur with increasing age can have significant effects on the pharmacokinetics of neuromuscular-blocking drugs. Changes in cardiac output can affect drug distribution and therefore the speed of onset of neuromuscular block. A decrease in muscle mass and increase in body fat with age can also affect their distribution. The deterioration in renal and hepatic function associated with aging affects the clearance and elimination of many neuromuscular-blocking drugs. The effects of these physiological changes on the pharmacokinetics of neuromuscular-blocking agents may not become apparent clinically in healthy individuals until the age of at least 75 years. There is very little evidence to suggest any alteration in the sensitivity of the neuromuscular junction to neuromuscular-blocking drugs with increasing age.

Neuromuscular-blocking drugs that undergo a significant degree of organ-dependent elimination, such as pancuronium bromide, vecuronium bromide, rocuronium bromide and doxacurium chloride, may have a significantly prolonged duration of action in elderly patients. These drugs can be used safely in elderly patients if the anaesthetist is aware of their altered pharmacokinetics in this patient group. Appropriate changes must be made to drug dosage and dose intervals. As the pharmacokinetic changes can be unpredictable, monitoring of neuromuscular block is strongly advised when using these drugs in such patients. The risk of residual block occurring postoperatively after the use of pancuronium bromide increases with age. The duration of action of mivacurium chloride may also be prolonged in the elderly; this change has not been demonstrated to be a result of an alteration in plasma cholinesterase activity. In contrast, there is no evidence of an alteration in the action of suxamethonium chloride (succinylchol-ine chloride) with increasing age.

Atracurium besilate and cisatracurium besilate undergo predominantly organ-independent elimination. Onset of block with these two drugs may be prolonged in the elderly, but their clinical duration of action does not alter significantly with age, making them particularly suitable for use in this patient group. Although atracurium besilate may cause histamine release, there is little evidence of it producing haemodynamic changes in the elderly. Its (1R,1R′)-isomer, cisatracurium besilate, has very little direct or indirect cardiovascular effect and is, therefore, the most suitable nondepolarising agent to use in elderly patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Table II
Table III
Table IV
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Viby-Mogensen J, Ostergaard D, Donati F, et al. Pharmacokinetic studies of neuromuscular blocking agents: good clinical research practice (GCRP). Acta Anaesthesiol Scand 2000; 44: 1169–90

    Article  PubMed  CAS  Google Scholar 

  2. Marshall CA. Influence of co-existing disease on anaesthetic management. In: Aitkenhead AR, Jones RM, editors. Clinical anaesthesia. Edinburgh: Churchill Livingstone, 1996: 31–77

    Google Scholar 

  3. Evers BM, Townsend Jr CM, Thompson JC. Organ physiology of aging. Surg Clin North Am 1994; 74: 23–39

    PubMed  CAS  Google Scholar 

  4. Gariepy LP, Varin F, Donati F, et al. Influence of aging on the pharmacokinetics and pharmacodynamics of doxacurium. Clin Pharmacol Ther 1993; 53: 340–7

    Article  PubMed  CAS  Google Scholar 

  5. Ornstein E, Lien CA, Matteo RS, et al. Pharmacodynamics and pharmacokinetics of cisatracurium in geriatric surgical patients. Anesthesiology 1996; 84: 520–5

    Article  PubMed  CAS  Google Scholar 

  6. Parker CJ, Hunter JM, Snowdon SL. Effect of age, sex and anaesthetic technique on the pharmacodynamics of atracur-ium. Br J Anaesth 1993; 70: 38–41

    Article  PubMed  CAS  Google Scholar 

  7. Wahba WM. The influence of aging on lung function: clinical significance of changes from age twenty. Anesth Analg 1983; 62: 764–76

    Article  PubMed  CAS  Google Scholar 

  8. Berg H, Viby-Mogensen J, Roed J, et al. Residual neuromuscular block is a risk factor for postoperative pulmonary complications: a prospective, randomised and blinded study of postoperative pulmonary complications after atracurium, vecuronium and pancuronium. Acta Anaesthesiol Scand 1997; 41: 1095–103

    Article  PubMed  CAS  Google Scholar 

  9. Matteo RS, Brotherton WP. Pharmacokinetics and pharmacodynamics of d-tubocurarine and metocurine in the elderly. Anesth Analg 1985; 64: 23–9

    PubMed  CAS  Google Scholar 

  10. Lien CA, Matteo RS, Ornstein E, et al. Distribution, elimination, and action of vecuronium in the elderly. Anesth Analg 1991; 73: 39–42

    Article  PubMed  CAS  Google Scholar 

  11. Kent AP, Parker CJ, Hunter JM. Pharmacokinetics of atracurium and laudanosine in the elderly. Br J Anaesth 1989; 63: 661–6

    Article  PubMed  CAS  Google Scholar 

  12. Fisher DM, Canfell PC, Fahey MR, et al. Elimination of atracurium in humans: contribution of Hofmann elimination and ester hydrolysis versus organ-based elimination. Anesthesiology 1986; 65: 6–12

    Article  PubMed  CAS  Google Scholar 

  13. Slavov V, Khalil M, Merle JC, et al. Comparison of duration of neuromuscular blocking effect of atracurium and vecuronium in young and elderly patients. Br J Anaesth 1994; 73: 608–12

    Article  Google Scholar 

  14. Kisor DF, Schmith VD, Wargin WA, et al. Importance of the organ-independent elimination of cisatracurium. Anesth Analg 1996; 83: 1065–71

    PubMed  CAS  Google Scholar 

  15. Cook DR, Stiller RL, Weakly JN, et al. In vitro metabolism of mivacurium chloride (BW B1090U) and succinylcholine. Anesth Analg 1989; 68: 452–6

    Article  PubMed  CAS  Google Scholar 

  16. Maddineni VR, Mirakhur RK, McCoy EP, et al. Neuromuscular and haemodynamic effects of mivacurium in elderly and young adult patients. Br J Anaesth 1994; 73: 608–12

    Article  PubMed  CAS  Google Scholar 

  17. Cook DR, Freeman JA, Lai AA, et al. Pharmacokinetics and pharmacodynamics of doxacurium in normal patients and those with hepatic or renal failure. Anesth Analg 1991; 72: 145–50

    Article  PubMed  CAS  Google Scholar 

  18. Dresner DL, Basta SJ, Ali HH, et al. Pharmacokinetics and pharmacodynamics of doxacurium in young and elderly patients during isoflurane anesthesia. Anesth Analg 1990; 71: 498–502

    Article  PubMed  CAS  Google Scholar 

  19. Matteo RS, Lieberman IG, Salanitre E, et al. Distribution, elimination and action of d-tubocurarine in neonates, infants, children and adults. Anesth Analg 1984; 63: 799–804

    Article  PubMed  CAS  Google Scholar 

  20. Meijer DK, Weitering JG, Scaf AH. Comparative pharmacokinetics of d-tubocurarine and metocurine in man. Anesthesiology 1979; 51: 402–7

    Article  PubMed  CAS  Google Scholar 

  21. Upton RA, Nguyen TL, Miller RD, et al. Renal and biliary elimination of vecuronium (ORG NC 45) and pancuronium in rats. Anesth Analg 1982; 61: 313–6

    Article  PubMed  CAS  Google Scholar 

  22. Duvaldestin P, Saada J, Berger JL, et al. Pharmacokinetics, pharmacodynamics, and dose-response relationships of pancuronium in control and elderly subjects. Anesthesiology 1982; 56: 36–40

    Article  PubMed  CAS  Google Scholar 

  23. Bencini AF, Scaf AHJ, De Wit APM, et al. Disposition of vecuronium bromide in the cat. Br J Anaesth 1985; 57: 782–8

    Article  PubMed  CAS  Google Scholar 

  24. McCarthy G, Elliot P, Mirakhur RK, et al. Onset and duration of action of vecuronium in the elderly: comparison with adults. Acta Anaesthesiol Scand 1992; 36: 383–6

    Article  PubMed  CAS  Google Scholar 

  25. Wierda JM, Szenohradszky J, de Wit AP, et al. The pharmacokinetics, urinary and biliary excretion of pipecuronium bromide. Eur J Anaesthesiol 1991; 8: 451–7

    PubMed  CAS  Google Scholar 

  26. Ornstein E, Matteo RS, Schwartz AE, et al. Pharmacokinetics and pharmacodynamics of pipecuronium bromide (Arduan) in elderly surgical patients. Anesth Analg 1992; 74: 841–4

    Article  PubMed  CAS  Google Scholar 

  27. Khuenl-Brady K, Castagnoli KP, Canfell PC, et al. The neuro-muscular blocking effects and pharmacokinetics of ORG 9426 and ORG 9616 in the cat. Anesthesiology 1990; 72: 669–74

    Article  PubMed  CAS  Google Scholar 

  28. Matteo RS, Ornstein E, Schwartz AE, et al. Pharmacokinetics and pharmacodynamics of rocuronium (Org 9426) in elderly surgical patients. Anesth Analg 1993; 77: 1193–7

    Article  PubMed  CAS  Google Scholar 

  29. van den Broek L, Wierda JM, Smeulers NJ, et al. Clinical pharmacology of rocuronium (Org 9426): study of the time course of action, dose requirement, reversibility, and pharmacokinetics. J Clin Anesth 1994; 6: 288–96

    Article  PubMed  Google Scholar 

  30. Bevan DR, Fiset P, Balendran P, et al. Pharmacodynamic behaviour of rocuronium in the elderly. Can J Anaesth 1993; 40: 127–32

    Article  PubMed  CAS  Google Scholar 

  31. Szenohradsky J, Caldwell JE, Wright PM, et al. Influence of renal failure on the pharmacokinetics and neuromuscular effects of a single dose of rapacuronium bromide. Anesthesiology 1999; 90: 24–35

    Article  Google Scholar 

  32. Kahwaji R, Bevan DR, Bikhazi G, et al. Dose-ranging study in younger adults and elderly patients of ORG 9487, a new, rapid onset, short-duration muscle relaxant. Anesth Analg 1997; 84: 1011–8

    PubMed  CAS  Google Scholar 

  33. Schiere S, Proost JH, Schuringa M, et al. Pharmacokinetics and pharmacokinetic-dynamic relationship between rapacuronium (Org 9487) and its 3-desacetyl metabolite (Org 9488). Anesth Analg 1999; 88: 640–7

    PubMed  CAS  Google Scholar 

  34. Verbeeck RK, Cardinal J, Wallace SM. Effect of age and sex on the plasma binding of acidic and basic drugs. Eur J Clin Pharmacol 1984; 27: 91–7

    PubMed  CAS  Google Scholar 

  35. Veering BT, Burm AG, Souverijn JH, et al. The effect of age on serum concentration of albumin and alpha 1-acid glyco-protein. Br J Clin Pharmacol 1990; 29: 201–6

    Article  PubMed  CAS  Google Scholar 

  36. Salive ME, Cornoni-Huntley J, Phillips CL, et al. Serum albumin in older persons: relationship with age and health status. J Clin Epidemiol 1992; 45: 213–21

    Article  PubMed  CAS  Google Scholar 

  37. Cameron M, Donati F, Varin F. In vitro plasma protein binding of neuromuscular blocking agents in different subpopulations of patients. Anesth Analg 1995; 81: 1019–25

    PubMed  CAS  Google Scholar 

  38. Duvaldestin P, Henzel D. Binding of tubocurarine, fazadinium, pancuronium and Org NC45 to serum proteins in normal man and in patients with cirrhosis. Br J Anaesth 1982; 54: 513–6

    Article  PubMed  CAS  Google Scholar 

  39. Wood M, Stone WJ, Wood AJJ. Plasma binding of pancuronium: effects of age, sex and disease. Anesth Analg 1983; 62: 29–32

    Article  PubMed  CAS  Google Scholar 

  40. Ghonheim MM, Kramer E, Bannow R, et al. Binding of d-tubo-curarine to plasma proteins in normal man and in patients with hepatic or renal disease. Anesthesiology 1973; 39: 410–5

    Article  Google Scholar 

  41. Lynam DP, Cronnelly R, Castagnoli KP, et al. The pharmacodynamics and pharmacokinetics of vecuronium in patients anesthetized with isoflurane with normal renal function or with renal failure. Anesthesiology 1988; 69: 227–31

    Article  PubMed  CAS  Google Scholar 

  42. Meistelman C, Lienhart A, Leveque C, et al. Pharmacology of vecuronium in patients with end-stage renal failure. Eur J Anaesthesiol 1986; 3: 153–8

    PubMed  CAS  Google Scholar 

  43. Bevan DR, Donati F, Gyasi H, et al. Vecuronium in renal failure. Can J Anaesth 1984; 31: 491–6

    Article  CAS  Google Scholar 

  44. Beauvoir C, Peray P, Daures JP, et al. Pharmacodynamics of vecuronium in patients with and without renal failure: a meta-analysis. Can J Anaesth 1993; 40: 696–702

    Article  PubMed  CAS  Google Scholar 

  45. Lepage JY, Malinge M, Cozian A, et al. Vecuronium and atracurium in patients with end-stage renal failure: a comparative study. Br J Anaesth 1987; 59: 1004–10

    Article  PubMed  CAS  Google Scholar 

  46. Lebrault C, Duvaldestin P, Henzel D, et al. Pharmacokinetics and pharmacodynamics of vecuronium in patients with cho-lestasis. Br J Anaesth 1986; 58: 983–7

    Article  PubMed  CAS  Google Scholar 

  47. Bencini AF, Scaf AH, Sohn YJ, et al. Hepatobiliary disposition of vecuronium bromide in man. Br J Anaesth 1986; 58: 988–95

    Article  PubMed  CAS  Google Scholar 

  48. Lukin CL, Hein HA, Swygert TH, et al. Duration of vecuronium-induced neuromuscular block as a predictor of liver allograft dysfunction. Anesth Analg 1995; 80: 526–33

    PubMed  CAS  Google Scholar 

  49. Kitts JB, Fisher DM, Canfell PC, et al. Pharmacokinetics and pharmacodynamics of atracurium in the elderly. Anesthesiology 1990; 72: 272–5

    Article  PubMed  CAS  Google Scholar 

  50. Sorooshian SS, Stafford MA, Eastwood NB, et al. Pharmacokinetics and pharmacodynamics of cisatracurium in young and elderly adult patients. Anesthesiology 1996; 84: 1083–91

    Article  PubMed  CAS  Google Scholar 

  51. Cook DR, Freeman JA, Lai AA, et al. Pharmacokinetics of mivacurium in normal patients and in those with hepatic or renal failure. Br J Anaesth 1992; 69: 580–5

    Article  PubMed  CAS  Google Scholar 

  52. Rupp SM, Castagnoli KP, Fisher DM, et al. Pancuronium and vecuronium pharmacokinetics and pharmacodynamics in younger and elderly adults. Anesthesiology 1987; 67: 45–9

    Article  PubMed  CAS  Google Scholar 

  53. Fisher DM, Kahwaji R, Bevan D, et al. Factors effecting the pharmacokinetic characteristics of rapacuronium. Anesthesiology 1999; 90: 993–1000

    Article  PubMed  CAS  Google Scholar 

  54. Bell PF, Mirakhur RK, Clarke RS. Dose-response studies of atracurium, vecuronium and pancuronium in the elderly. Anaesthesia 1989; 44: 925–7

    Article  PubMed  CAS  Google Scholar 

  55. Kurtz A, Plattner O, Sessler DI, et al. The threshold for thermo-regulatory vasoconstriction during nitrous oxide/isoflurane anesthesia is lower in the elderly than in young patients. Anesthesiology 1993; 79: 465–9

    Article  Google Scholar 

  56. Diefenbach C, Abel M, Buzello W. Greater neuromuscular blocking potency of atracurium during hypothermie than during normothermic cardiopulmonary bypass. Anesth Analg 1992; 75: 675–8

    Article  PubMed  CAS  Google Scholar 

  57. Buzello W, Schluermann D, Pollmaecher T, et al. Unequal effects of cardiopulmonary bypass-induced hypothermia on neuromuscular blockade from constant infusion of alcuron-ium, d-tubocurarine, pancuronium and vecuronium. Anesthesiology 1987; 66: 842–6

    Article  PubMed  CAS  Google Scholar 

  58. Buzello W, Schluermann D, Spillner G. Hypothermic cardiopulmonary bypass and neuromuscular blockade by pancuronium and vecuronium. Anesthesiology 1985; 62: 201–4

    Article  PubMed  CAS  Google Scholar 

  59. Heier T, Caldwell JE, Sessler DI, et al. Mild intraoperative hypothermia increases duration of action and spontaneous recovery of vecuronium blockade during nitrous oxide: isoflurane anesthesia in humans. Anesthesiology 1991; 74: 815–9

    Article  PubMed  CAS  Google Scholar 

  60. Maddineni VR, Mirakhur RK, McCoy EP. Plasma cholinester-ase activity in elderly and young adults [letter]. Br J Anaesth 1994; 72: 497

    Article  PubMed  CAS  Google Scholar 

  61. Viby-Mogensen J. Correlation of succinylcholine duration of action with plasma cholinesterase activity in subjects with the genotypically normal enzyme. Anesthesiology 1980; 53: 517–20

    Article  PubMed  CAS  Google Scholar 

  62. Parker CJ, Hunter JM, Snowdon SL. Effect of age, sex and anaesthetic technique on the pharmacokinetics of atracurium. Br J Anaesth 1992; 69: 439–43

    Article  PubMed  CAS  Google Scholar 

  63. Shorten GD, Goudsouzian NG, Ali HH. Histamine release following atracurium in the elderly. Anaesthesia 1993; 48: 568–71

    Article  PubMed  CAS  Google Scholar 

  64. Mellinghoff H, Radbruch L, Diefenbach C, et al. A comparison of cisatracurium and atracurium: onset of neuromuscular block after bolus injection and recovery after subsequent infusion. Anesth Analg 1996; 83: 1072–5

    PubMed  CAS  Google Scholar 

  65. Welch RM, Brown A, Ravitch J, et al. The in vitro degradation of cisatracurium, the R, cis-R’-isomer of atracurium, in human and rat plasma. Clin Pharmacol Ther 1995; 58: 132–42

    Article  PubMed  CAS  Google Scholar 

  66. Doenicke AW, Czeslick E, Moss J, et al. Onset time, endotra-cheal intubating conditions, and plasma histamine after cisatracurium and vecuronium administration. Anesth Analg 1998; 87: 434–8

    PubMed  CAS  Google Scholar 

  67. Doenicke AW, Soukup J, Hoernecke R, et al. Lack of histamine release with cisatracurium: a double-blind comparison with vecuronium. Anesth Analg 1997; 84: 623–8

    PubMed  CAS  Google Scholar 

  68. Devlin JC, Head-Rapson AG, Parker CJ, et al. Pharmacody-namics of mivacurium chloride in patients with hepatic cirrhosis. Br J Anaesth 1993; 71: 227–31

    Article  PubMed  CAS  Google Scholar 

  69. Ostergaard D, Jensen FS, Skovgaard LT, et al. Dose-response relationship for mivacurium in patients with phenotypically abnormal plasma cholinesterase activity. Acta Anaesthesiol Scand 1995; 39: 1016–8

    Article  PubMed  CAS  Google Scholar 

  70. Goudsouzian NG, d’Hollander AA, Viby-Mogensen J. Prolonged neuromuscular block from mivacurium in two patients with cholinesterase deficiency. Anesth Analg 1993; 77: 183–5

    Article  PubMed  CAS  Google Scholar 

  71. Dahaba AA, Rehak PH, List WF. A comparison of mivacurium infusion requirements between young and elderly adult patients. Eur J Anaesthesiol 1996; 13: 43–8

    Article  PubMed  CAS  Google Scholar 

  72. Goudsouzian N, Nishan MD, Chakravorti S, et al. Prolonged mivacurium infusion in young and elderly adults. Can J Anaesth 1997; 44: 955–62

    Article  PubMed  CAS  Google Scholar 

  73. Whittaker M. Plasma cholinesterase variants and the anaesthetist. Anaesthesia 1980; 35: 174–97

    Article  PubMed  CAS  Google Scholar 

  74. Montamed C, Donati F. Intubating conditions and blockade after mivacurium, rocuronium and their combination in young and elderly adults. Can J Anaesth 2000; 47: 225–31

    Article  Google Scholar 

  75. Martlew RA, Harper NJ. The clinical pharmacology of doxacur-ium in young adults and in elderly patients. Anaesthesia 1995; 50: 779–82

    Article  PubMed  CAS  Google Scholar 

  76. De Mey JC, Roily G, Den Blauwen N. Doxacurium block is not influenced by age. J Clin Anesth 1995; 7: 453–6

    Article  PubMed  Google Scholar 

  77. McLeod K, Hull CJ, Watson MJ. Effects of ageing on the phar-macokinetics of pancuronium. Br J Anaesth 1979; 51: 435–8

    Article  PubMed  CAS  Google Scholar 

  78. Shorten GD, Uppington J, Comunale ME. Changes in plasma catecholamine concentrations and haemodynamic effects of rocuronium and vecuronium in elderly patients. Eur J Anaesthesiol 1998; 15: 335–41

    PubMed  CAS  Google Scholar 

  79. Fisher DM, Dempsey GA, Atherton PL, et al. Effect of renal failure and cirrhosis on the pharmacokinetics and neuromuscular effects of rapacuronium administered by bolus followed by infusion. Anesthesiology 2000; 93: 1384–91

    Article  PubMed  CAS  Google Scholar 

  80. Marsh RH, Chmielewski AT, Goat VA. Recovery from pancuronium: a comparison between young and old patients. Anaesthesia 1980; 35: 1193–6

    Article  PubMed  CAS  Google Scholar 

  81. Young WL, Backus W, Matteo RS, et al. Pharmacokinetics and pharmacodynamics of neostigmine in the elderly [abstract]. Anesthesiology 1984; 61: 3A

    Article  Google Scholar 

  82. Young WL, Matteo RS, Ornstein E. Duration of action of neostigmine and pyridostigmine in the elderly. Anesth Analg 1988; 67: 775–8

    PubMed  CAS  Google Scholar 

  83. Vandenbrom RH, Wierda JM. Pancuronium bromide in the intensive care unit: a case of overdose. Anesthesiology 1988; 69: 996–7

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors have provided no information on sources of funding or on conflicts of interest directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. University Hospital Aintree, Liverpool, UK

    Tristan M. Cope

  2. University Department of Anaesthesia, University of Liverpool, Liverpool, UK

    Jennifer M. Hunter

Authors
  1. Tristan M. Cope
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jennifer M. Hunter
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jennifer M. Hunter.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cope, T.M., Hunter, J.M. Selecting Neuromuscular-Blocking Drugs for Elderly Patients. Drugs & Aging 20, 125–140 (2003). https://doi.org/10.2165/00002512-200320020-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200320020-00004

Keywords

Search

Navigation